Everolimus Structural Formula (Afinitor 01)
Afinitor Tablet
Product Images NDC 0078-0566
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 43 technical images submitted to the FDA as part of the official labeling for Afinitor (NDC 0078-0566). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2: Kaplan-meier Investigator-determined Progression-free Survival Curves (Afinitor 02)
This is a statistical report on the probability of a hazard ratio with corresponding confidence intervals, p-value, and Kaplan-Meier medians based on a clinical trial comparing the effectiveness of Afinitor and Placebo. The data shows that Afinitor had a significantly longer duration of survival compared to Placebo. The data also includes a graph of the censoring times for both treatment groups over time.*
Figure 4: Kaplan-meier Progression-free Survival Curves (Afinitor 03)
This text provides information on the results of a study or experiment. It includes percentages and hazard ratio with confidence intervals. The logrank p-value is also given. There are two treatments compared: Afinitor and Placebo. The Kaplan-Meier medians are shown for both treatments in terms of months. Additionally, censoring times are provided for both treatments. The time (in months) is listed at the end.*
Principal Display Panel Ndc 0078-0594-51 Rx Only 28 Tablets Carton Contains 4 Individual Blister Cards Of 7 Tablets. Afinitor® (everolimus) Tablets Each Tablet Contains 2.5 mg Everolimus Novartis (Afinitor 04)
This is a description of a box of 28 tablets of Afinitor (everolimus) made by Novartis. The box is labeled with the drug's name and information including contact information for more information. The tablets are only available by prescription. The also included some irregular characters, so the description is not exact, but it reflects what's clear from the text.*
Principal Display Panel Ndc 0078-0566-51 Rx Only 28 Tablets Carton Contains 4 Individual Blister Cards Of 7 Tablets. Afinitor® (everolimus) Tablets Each Tablet Contains 5 mg Everolimus Novartis (Afinitor 05)
This appears to be a description of several tablets containing everolimus, marketed under the brand names AFINITOR and BARCINATOR, in 28-tablet blister cards. The NDC code for the AFINITOR tablets is 0078056651, and their manufacturer is Novartis. The text also provides a phone number and website for obtaining more information about the tablets.*
Principal Display Panel Ndc 0078-0567-51 Rx Only 28 Tablets Carton Contains 4 Individual Blister Cards Of 7 Tablets. Afinitor® (everolimus) Tablets Each Tablet Contains 10 mg Everolimus Novartis (Afinitor 06)
This text appears to be from a medication package of AFINITOR tablets, which contain 10mg of everolimus. The package contains 28 tablets and is only available with a prescription. The manufacturer of the medication is Novartis. More information about the medication is available by visiting www.AFINTOR.com or contacting a toll-free number.*
Principal Display Panel Ndc 0078-0620-51 Rx Only 28 Tablets Carton Contains 4 Individual Blister Cards Of 7 Tablets. Afinitor® (everolimus) Tablets Each Tablet Contains 7.5 mg Everolimus Novartis (Afinitor 07)
AFINITOR is a medication contained in a box of 28 tablets with a NDC number of 0078062051. Each tablet contains everolimus and is Rx-only. For more information about AFINITOR, visit their website or call their hotline.*
Figure 1: Kaplan-meier Progression-free Survival Curves (investigator Radiological Review) (Afinitor 08)
The text provides information on the progression-free survival probability of two different treatments, Everolimus 10mg - exemestane, and Placebo-exemestane. The Kaplan-Meier medians indicate that Everolimus has a median progression-free survival probability of 7.8 months while the Placebo-exemestane treatment has a median progression-free survival probability of 32 months. The log-rank p-value is <0001 and there were four censoring times. The text also includes a graph representing the progression-free survival probability over time (in months) for both treatments.*
Principal Display Panel Ndc 0078-0626-51 Rx Only 28 Tablets For Oral Suspension Carton Contains 4 Individual Blister Cards Of 7 Tablets. Afinitor Disperz® (everolimus Tablets For Oral Suspension) 2 mg Tablets Must Be Dispersed In Water. Tablets Must Not Be Swallowed Whole, Chewed Or Crushed. Each Tablet Contains 2 mg Everolimus Novartis (Afinitor 09)
This appears to be a medication information leaflet for AFINITOR DISPERZ - a brand of everolimus tablets for oral suspension used for treating certain types of cancer. The text mentions the dosage (2mg), and instructions cautioning against swallowing the tablets whole, chewing, or crushing them.*
Figure A (Afinitor 0a)
Figure B (Afinitor 0b)
Figure C (Afinitor 0c)
Figure D (Afinitor 0d)
Figure E (Afinitor 0e)
Figure F (Afinitor 0f)
Figure G (Afinitor 0g)
Figure H (Afinitor 0h)
Figure I (Afinitor 0i)
Figure J (Afinitor 0j)
Figure K (Afinitor 0k)
Figure L (Afinitor 0l)
Figure M (Afinitor 0m)
Figure N (Afinitor 0n)
Figure O (Afinitor 0o)
Figure P (Afinitor 0p)
Figure Q (Afinitor 0q)
Figure R (Afinitor 0r)
Figure S (Afinitor 0s)
Figure T (Afinitor 0t)
Figure U (Afinitor 0u)
Figure V (Afinitor 0v)
Figure W (Afinitor 0w)
Figure X (Afinitor 0x)
Figure Y (Afinitor 0y)
Figure Z (Afinitor 0z)
Principal Display Panel Ndc 0078-0627-51 Rx Only 28 Tablets For Oral Suspension Carton Contains 4 Individual Blister Cards Of 7 Tablets. Afinitor Disperz® (everolimus Tablets For Oral Suspension) 3 mg Tablets Must Be Dispersed In Water. Tablets Must Not Be Swallowed Whole, Chewed Or Crushed. Each Tablet Contains 3 mg Everolimus Novartis (Afinitor 10)
AFINITOR DISPERZ is a medication that comes in tablet form containing everolimus and is available in a strength of 3mg. The tablets must not be swallowed whole, chewed or crushed. They must be dispersed in water before consumption. The provided text seems to be a warning or instruction for proper medication intake.*
Principal Display Panel Ndc 0078-0628-51 Rx Only 28 Tablets For Oral Suspension Carton Contains 4 Individual Blister Cards Of 7 Tablets. Afinitor Disperz® (everolimus Tablets For Oral Suspension) 5 mg Tablets Must Be Dispersed In Water. Tablets Must Not Be Swallowed Whole, Chewed Or Crushed. Each Tablet Contains 5 mg Everolimus Novartis (Afinitor 11)
This is a description of medication called AFINITOR DISPERZ (everolimus tablets for oral suspension) available in 5mg strength. The tablets should not be swallowed whole or chewed. They must be dispersed in water before taking. There are additional details about the product that are not available in the provided text.*
Figure 3: Kaplan-meier Progression-free Survival Curves (Afinitor 12)
This appears to be a graph displaying the probability of an event over time (in months) for two groups of patients - one group on Everolimus + BSC and the other on Placebo + BSC. The number of patients at risk for each group is also shown over time.*
Figure Aa (Afinitor Aa)
Figure Bb (Afinitor Bb)
Figure Cc (Afinitor Cc)
Figure Dd (Afinitor Dd)
Figure Ee (Afinitor Ee)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
